within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03E_AndrogensAndFemaleSexHormonesInCombination.G03EA03_PrasteroneAndEstrogen;

model PrasteroneAndEstrogen
  extends Pharmacolibrary.Drugs.ATC.G.G03EA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>G03EA03</td></tr><td>route:</td><td>vaginal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Prasterone (dehydroepiandrosterone, DHEA) and estrogen combination is a hormonal therapy used for the treatment of symptoms associated with menopause, such as vulvar and vaginal atrophy. This drug is not widely approved as a combination product; DHEA and estrogens are available separately for specific indications related to hormone replacement.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic model or direct pharmacokinetic parameter data for the combination of prasterone and estrogen with ATC code G03EA03 was found in the literature as of 2024. The pharmacokinetics must be estimated from known monotherapy parameters of DHEA and estrogens, but there are no direct studies or population PK models specific to the combination product.</p><h4>References</h4><ol><li><p>Smith, T, et al., &amp; Thacker, HL (2020). Postmenopausal Hormone Therapy-Local and Systemic: A Pharmacologic Perspective. <i>Journal of clinical pharmacology</i> 60 Suppl 2 S74–S85. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1740&quot;>10.1002/jcph.1740</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33274517/&quot;>https://pubmed.ncbi.nlm.nih.gov/33274517</a></p></li><li><p>Holton, M, et al., &amp; Goldstein, AT (2020). An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. <i>Expert opinion on pharmacotherapy</i> 21(4) 409–415. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2019.1703951&quot;>10.1080/14656566.2019.1703951</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31928093/&quot;>https://pubmed.ncbi.nlm.nih.gov/31928093</a></p></li><li><p>Labrie, F, et al., &amp; Balser, J (2009). Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. <i>Menopause (New York, N.Y.)</i> 16(5) 897–906. DOI:<a href=&quot;https://doi.org/10.1097/gme.0b013e31819e8930&quot;>10.1097/gme.0b013e31819e8930</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19436226/&quot;>https://pubmed.ncbi.nlm.nih.gov/19436226</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end PrasteroneAndEstrogen;
